DUBLIN, Ohio--(BUSINESS WIRE)--Neoprobe Corporation (OTCBB:NEOP), a diversified developer of innovative oncology and cardiovascular surgical and diagnostic products, today announced that final results from a multi-center Phase 2 clinical study were presented at the 61st Annual Cancer Symposium of the Society of Surgical Oncology in Chicago, Illinois. The Phase 2 clinical study was conducted in 80 patients with either melanoma or breast cancer. Five leading cancer treatment centers participated in the study. The Phase 2 study was designed to test the effectiveness of Lymphoseek in identifying lymphatic tissue and to evaluate the drug safety of the compound.
